Nanoparticle-mediated local delivery of an antisense TGF-β1 construct inhibits intimal hyperplasia in autogenous vein grafts in rats

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Sun, Da Xin ^a   Liu, Zhen ^a   Tan, Xiao Dong ^a   Cui, Dong Xu ^a   Wang, Bao Sheng ^a   Dai, Xian Wei ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; INTERSTITIAL COLLAGENASE; NANOPARTICLE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTISENSE THERAPY; ARTERY INTIMA PROLIFERATION; ARTICLE; CAROTID ARTERY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; INTERNAL JUGULAR VEIN; MALE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PROTEIN EXPRESSION; RAT; VEIN GRAFT;

ANIMALS; CAROTID ARTERIES; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; HYPERPLASIA; JUGULAR VEINS; MALE; MATRIX METALLOPROTEINASE 1; NANOPARTICLES; NEOINTIMA; OLIGORIBONUCLEOTIDES, ANTISENSE; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, WISTAR; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA INTERFERENCE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSFORMING GROWTH FACTOR BETA1; TRANSPLANTATION, AUTOLOGOUS; TUNICA INTIMA; VASCULAR GRAFTING;

RATTUS;

EID: 84864422901     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041857     Document Type: Article

References (32)

1. Schwartz RS, Holmes DR Jr, Topol EJ, ((1992)) The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol 20:: 1284--1293.
2. Friedl R, Li J, Schumacher B, Hanke H, Waltenberger J, et al. ((2004)) Intimal hyperplasia and expression of transforming growth factor-beta1 in saphenous veins and internal mammary arteries before coronary artery surgery. Ann Thorac Surg 78:: 1312--1318.
3. Kingston PA, Sinha S, David A, Castro MG, Lowenstein PR, et al. ((2001)) Adenovirus-mediated gene transfer of a secreted transforming growth factor-beta type II receptor inhibits luminal loss and constrictive remodeling after coronary angioplasty and enhances adventitial collagen deposition. Circulation 104:: 2595--2601.
4. Newby AC, ((2005)) Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 85:: 1--31.
5. Papazafiropoulou A, Tentolouris N, ((2009)) Matrix metalloproteinases and cardiovascular diseases. Hippokratia 13:: 76--82.
6. Khan R, Agrotis A, Bobik A, ((2007)) Understanding the role of transforming growth factor-β1 in intimal thickening after vascular injury. Cardiovasc Res 74:: 223--234.
7. Majeski MW, Lindner V, Twardzik DR, Schwartz SM, Reidy MA, ((1991)) Production of transforming growth factor beta 1 during repair of arterial injury. J Clin Invest 88:: 904--910.
8. Nikol S, Isner JM, Pickering JG, Kearney M, Leclerc G, et al. ((1992)) Expression of transforming growth factor- beta I is increased in human vascular restenosis lesions. J Clin Invest 90:: 1582--1592.
9. Kanzaki T, Tamura K, Takahashi K, Saito Y, Akikusa B, et al. ((1995)) In vivo effect of TGF-beta 1. Enhanced intimal thickening by administration of TGF-beta 1 in rabbit arteries injured with a balloon catheter. Arterioscler Thromb Vasc Biol 15:: 1951--1957.
10. Nabel EG, Shum L, Pompili VJ, Yang Z-Y, San H, et al. ((1993)) Direct transfer of transforming growth factor j81 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci USA 90:: 10759--10763.
11. Wolf YG, Rasmussen LM, Ruoslahti E, ((1994)) Antibodies against transforming growth factor-beta 1 suppress intimal hyperplasia in a rat model. J Clin Invest 93:: 1172--1178.
12. Mallat Z, Gojova A, Marchiol-Fournigault C, Esposito B, Kamaté C, et al. ((2001)) Inhibition of transforming growth factor-β signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res 89:: 930--934.
13. Robertson AK, Rudling M, Zhou X, Gorelik L, Flavell RA, et al. ((2003)) Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J Clin Invest 112:: 1342--1350.
14. Kobayashi K, Yokote K, Fujimoto M, Yamashita K, Sakamoto A, et al. ((2005)) Targeted disruption of TGF-beta-Smad3 signaling leads to enhanced neointimal hyperplasia with diminished matrix deposition in response to vascular injury. Circ Res 96:: 904--912.
15. TamaiH, Katoh K, Yamaguchi T, HayakawaH KanmatsuseK, et al. ((2002)) The impact of tranilast on restenosis after coronary angioplasty: the Second Tranilast Restenosis Following Angioplasty Trial (TREAT-2).Am Heart J. 143:: 506--513.
16. Guzman LA, Labhasetwar V, Song C, Jang Y, Lincoff AM, et al. ((1996)) Local intraluminal infusion of biodegradable polymeric nanoparticles. A novel approach for prolonged drug delivery after balloon angioplasty. Circulation 94:: 1441--1448.
17. Chen Y, Xue Z, Zheng D, Xia K, Zhao Y, et al. ((2003)) Sodium chloride modified silica nanoparticles as a non-viral vector with a high efficiency of DNA transfer into cells. Curr Gene Ther 3:: 273--279.
18. Chamberlain J, Gunn J, Francis SE, Holt CM, Arnold ND, et al. ((2001)) TGFbeta is active, and correlates with activators of TGFbeta, following porcine coronary angioplasty. Cardiovasc Res 50:: 125--136.
19. Yutani C, Ishibashi-Ueda H, Suzuki T, Kojima A, ((1999)) Histologic evidence of foreign body granulation tissue and de novo lesions in patients with coronary stent restenosis. Cardiology 92:: 171--177.
20. Shi Y, Massagué J, ((2003)) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113:: 685--700.
21. Joshua DS, Shane RB, Leslie LC, Calvin HV, Philip JG, et al. ((1999)) Soluble transforming growth factor-beta type II receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth. Circ Res. 84:: 1212--1222.
22. Kubota K, Okazaki J, Louie O, Kent KC, Liu B, ((2003)) TGF-beta stimulates collagen (I) in vascular smooth muscle cells via a short element in the proximal collagen promoter. J Surg Res 109:: 43--50.
23. Wang M, Zhao D, Spinetti G, Zhang J, Jiang LQ, et al. ((2006)) Matrix metalloproteinase 2 activation of transforming growth factor-beta1 (TGF-beta1) and TGF-beta1-type II receptor signaling within the aged arterial wall. Arterioscler Thromb Vasc Biol 26:: 1503--1509.
24. Ward MR, Agrotis A, Kanellakis P, Hall J, Jennings G, et al. ((2002)) Tranilast prevents activation of transforming growth factor-beta system, leukocyte accumulation, and neointimal growth in porcine coronary arteries after stenting. Arterioscler Thromb Vasc Biol 22:: 940--948.
25. Merrilees M, Beaumont B, Scott L, Hermanutz V, Fennessy P, ((2000)) Effect of TGF-beta(1) antisense S-oligonucleotide on synthesis and accumulation of matrix proteoglycans in balloon catheter-injured neointima of rabbit carotid arteries. J Vasc Res 37:: 50--60.
26. Smith JD, Bryant SR, Couper LL, Vary CP, Gotwals PJ, et al. ((1999)) Soluble transforming growth factor-beta type II receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth. Circ Res 84:: 1212--1222.
27. Yamamoto K, Morishita R, Tomita N, Shimozato T, Nakagami H, et al. ((2000)) Ribozyme oligonucleotides against transforming growth factor-beta inhibited neointimal formation after vascular injury in rat model: potential application of ribozyme strategy to treat cardiovascular disease. Circulation 102:: 1308--1314.
28. Holmes Jr DR, Savage M, LaBlanche JM, Grip L, Serruys PW, et al. ((2002)) Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 106:: 1243--1250.
29. Medina C, Santos-Martinez MJ, Radomski A, Corrigan OI, Radomski MW, ((2007)) Nanoparticles: pharmacological and toxicological significance. Br J Pharmacol 150:: 552--558.
30. Davda J, Labhasetwar V, ((2002)) Characterization of nanoparticle uptake by endothelial cells. Int J Pharm 233:: 51--59.
31. Cohen-Sela E, Dangoor D, Epstein H, Gati I, Danenberg HD, et al. ((2006)) Nanospheres of a bisphosphonate attenuate intimal hyperplasia. J Nanosci Nanotechnol 6:: 3226--3234.
32. Banai S, Chorny M, Gertz SD, Fishbein I, Gao J, et al. ((2005)) Locally delivered nanoencapsulated tyrphosyin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries. Biomaterials 26:: 451--461.